RxDoctor Payments Data

Nathaniel Valin, MD

Cardiovascular Disease · Daytona Beach, FLNPI 1588646616

Payments from drug & device makers

$46,242in general payments, 2019–2025

Across 749 payments — averaging $61.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$15K
  • Medtronic$9K
  • Penumbra, Inc.$5K
  • Cardiovascular Systems Inc.$4K
  • Abiomed$4K
  • Boston Scientific$1K
  • plus $8K from 45 others

What the payments were for

  • Consulting fees$6,70017%
  • Speaking & faculty fees$3,3758%
  • Travel & lodging$11,02927%
  • Food & beverage$18,91547%
  • Education$2231%
  • Other$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,242 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$878,598
Medicare patients
1,341
Services billed
5,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban464$627,998
XareltoRivaroxaban240$276,788
JardianceEmpagliflozin96$117,894
EntrestoSacubitril/Valsartan68$81,637
BrilintaTicagrelor57$50,070
Repatha SureclickEvolocumab47$44,317
FarxigaDapagliflozin Propanediol22$34,326
MultaqDronedarone Hcl19$26,721
Metoprolol Succinate997$18,047
Repatha SyringeEvolocumab18$17,358
NexlizetBempedoic Acid/Ezetimibe11$12,206
Dabigatran EtexilateDabigatran Etexilate Mesylate36$11,690
Atorvastatin Calcium787$9,908
Ranolazine ErRanolazine86$9,421
ClopidogrelClopidogrel Bisulfate473$7,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$264$627,998464 claims
Johnson & JohnsonXarelto$1,169$276,788240 claims
Boehringer IngelheimJardiance$631$117,89496 claims
AstraZenecaBrilinta, Farxiga$204$84,39679 claims
NovartisEntresto$276$81,63768 claims
Sanofi-aventis U.S. LLCMultaq$299$26,72119 claims
Esperion Therapeutics, Inc.Nexlizet$169$12,20611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →